标题
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-02-02
DOI
10.3389/fimmu.2020.622509
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
- (2020) Meenu Sharma et al. Nature Communications
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
- (2020) Ugur Sahin et al. NATURE
- Exhausted CD8+ T cells exhibit low and strongly inhibited TCR signaling during chronic LCMV infection
- (2020) Ioana Sandu et al. Nature Communications
- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
- (2019) Sema Kurtulus et al. IMMUNITY
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
- (2019) Xindong Liu et al. NATURE
- Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections
- (2019) Mary Philip et al. CURRENT OPINION IN IMMUNOLOGY
- TOX is a critical regulator of tumour-specific T cell differentiation
- (2019) Andrew C. Scott et al. NATURE
- TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
- (2019) Omar Khan et al. NATURE
- Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection
- (2019) Chen Yao et al. NATURE IMMUNOLOGY
- PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
- (2019) Vivek Verma et al. NATURE IMMUNOLOGY
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
- (2019) Zeyu Chen et al. IMMUNITY
- Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
- (2019) William H. Hudson et al. IMMUNITY
- CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer
- (2019) Ryan Zander et al. IMMUNITY
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
- (2018) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- High-dimensional single cell analysis identifies stem-like cytotoxic CD8+T cells infiltrating human tumors
- (2018) Jolanda Brummelman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
- (2018) Hanjie Li et al. CELL
- CD4 + T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness
- (2017) Tomasz Ahrends et al. IMMUNITY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Exhaustion-associated regulatory regions in CD8+tumor-infiltrating T cells
- (2017) Giuliana P. Mognol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Dissection of CD8 + T-Cell Dysfunction
- (2017) Chao Wang et al. TRENDS IN IMMUNOLOGY
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
- (2016) Meromit Singer et al. CELL
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections
- (2016) Daniel T. Utzschneider et al. IMMUNITY
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells
- (2015) Pamela M. Odorizzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- Inhibitory Receptors Beyond T Cell Exhaustion
- (2015) Silvia A. Fuertes Marraco et al. Frontiers in Immunology
- Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
- (2014) L. Karyampudi et al. CANCER RESEARCH
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
- (2013) Daniel T Utzschneider et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tolerance and exhaustion: defining mechanisms of T cell dysfunction
- (2013) Andrea Schietinger et al. TRENDS IN IMMUNOLOGY
- Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
- (2013) D. B. Johnson et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory
- (2012) Travis A. Doering et al. IMMUNITY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection
- (2012) M. A. Paley et al. SCIENCE
- The three main stumbling blocks for anticancer T cells
- (2012) Lukas Baitsch et al. TRENDS IN IMMUNOLOGY
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model
- (2011) Yuwen Zhu et al. IMMUNITY
- Phenotype, Function, and Gene Expression Profiles of Programmed Death-1 hi CD8 T Cells in Healthy Human Adults
- (2011) Jaikumar Duraiswamy et al. JOURNAL OF IMMUNOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
- Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
- (2008) S. D. Blackburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More